Emerging Therapeutic Potential of Adeno-associated Virus-mediated Gene Therapy in Liver Fibrosis

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2022 Jul 21

PMID 35859692

Authors

Fang-Tian Bu

Peng-Cheng Jia

Yan Zhu

Ya-Ru Yang

Hong-Wu Meng

Yi-Hui Bi

Cheng Huang

Jun Li

Affiliations

Soon will be listed here.

Abstract

Liver fibrosis is a wound-healing response that results from various chronic damages. If the causes of damage are not removed or effective treatments are not given in a timely manner, it will progress to cirrhosis, even liver cancer. Currently, there are no specific medical therapies for liver fibrosis. Adeno-associated virus (AAV)-mediated gene therapy, one of the frontiers of modern medicine, has gained more attention in many fields due to its high safety profile, low immunogenicity, long-term efficacy in mediating gene expression, and increasingly known tropism. Notably, increasing evidence suggests a promising therapeutic potential for AAV-mediated gene therapy in different liver fibrosis models, which helps to correct abnormally changed target genes in the process of fibrosis and improve liver fibrosis at the molecular level. Moreover, the addition of cell-specific promoters to the genome of recombinant AAV helps to limit gene expression in specific cells, thereby producing better therapeutic efficacy in liver fibrosis. However, animal models are considered to be powerless predictive of tissue tropism, immunogenicity, and genotoxic risks in humans. Thus, AAV-mediated gene therapy will face many challenges. This review systemically summarizes the recent advances of AAV-mediated gene therapy in liver fibrosis, especially focusing on cellular and molecular mechanisms of transferred genes, and presents prospective challenges.

Citing Articles

Liver fibrosis negatively impacts in vivo gene transfer to murine hepatocytes.

Simoni C, Nozi J, Starinieri F, La Bella T, Manta E, Negri C Nat Commun. 2025; 16(1):2119.

PMID: 40064848 PMC: 11894088. DOI: 10.1038/s41467-025-57383-8.

Targeting thrombospondin-2 retards liver fibrosis by inhibiting TLR4-FAK/TGF-β signaling.

Zhang N, Wu X, Zhang W, Sun Y, Yan X, Xu A JHEP Rep. 2024; 6(3):101014.

PMID: 38379585 PMC: 10877131. DOI: 10.1016/j.jhepr.2024.101014.

Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets.

Di X, Gao X, Peng L, Ai J, Jin X, Qi S Signal Transduct Target Ther. 2023; 8(1):282.

PMID: 37518181 PMC: 10387486. DOI: 10.1038/s41392-023-01501-9.

Liver directed adeno-associated viral vectors to treat metabolic disease.

Chuecos M, Lagor W J Inherit Metab Dis. 2023; 47(1):22-40.

PMID: 37254440 PMC: 10687323. DOI: 10.1002/jimd.12637.

Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update.

Kolaric T, Kuna L, covic M, Roguljic H, Matic A, Sikora R Curr Issues Mol Biol. 2023; 45(5):4246-4260.

PMID: 37232739 PMC: 10216970. DOI: 10.3390/cimb45050270.

References

Yang Y, Wu X, Li W, Huang H, Li H, Pan X . PSTPIP2 connects DNA methylation to macrophage polarization in CCL4-induced mouse model of hepatic fibrosis. Oncogene. 2018; 37(47):6119-6135. DOI: 10.1038/s41388-018-0383-0. View

Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y . BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol. 2005; 290(1):L120-6. DOI: 10.1152/ajplung.00171.2005. View

Lo R, Kim H . Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017; 23(4):302-307. PMC: 5760001. DOI: 10.3350/cmh.2017.0078. View

Yang N, Mahato R . GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis. Pharm Res. 2011; 28(4):752-61. DOI: 10.1007/s11095-011-0384-y. View

George L, Sullivan S, Giermasz A, Rasko J, Samelson-Jones B, Ducore J . Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017; 377(23):2215-2227. PMC: 6029626. DOI: 10.1056/NEJMoa1708538. View

Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S . Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest. 2006; 116(7):1843-52. PMC: 1474816. DOI: 10.1172/JCI27282. View

Davidoff A, Gray J, Ng C, Zhang Y, Zhou J, Spence Y . Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther. 2005; 11(6):875-88. DOI: 10.1016/j.ymthe.2004.12.022. View

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

ATCHISON R, CASTO B, HAMMON W . ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES. Science. 1965; 149(3685):754-6. DOI: 10.1126/science.149.3685.754. View

10.

Pipe S, Leebeek F, Ferreira V, Sawyer E, Pasi J . Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer. Mol Ther Methods Clin Dev. 2019; 15:170-178. PMC: 6807344. DOI: 10.1016/j.omtm.2019.08.015. View

11.

Chen X, Li W, Chen Y, Li X, Li H, Huang H . Suppression of SUN2 by DNA methylation is associated with HSCs activation and hepatic fibrosis. Cell Death Dis. 2018; 9(10):1021. PMC: 6170444. DOI: 10.1038/s41419-018-1032-9. View

12.

Nidetz N, McGee M, Tse L, Li C, Cong L, Li Y . Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacol Ther. 2019; 207:107453. PMC: 6980784. DOI: 10.1016/j.pharmthera.2019.107453. View

13.

Hastie E, Samulski R . Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. Hum Gene Ther. 2015; 26(5):257-65. PMC: 4442590. DOI: 10.1089/hum.2015.025. View

14.

Tsui T, Lau C, Ma J, Glockzin G, Obed A, Schlitt H . Adeno-associated virus-mediated heme oxygenase-1 gene transfer suppresses the progression of micronodular cirrhosis in rats. World J Gastroenterol. 2006; 12(13):2016-23. PMC: 4087678. DOI: 10.3748/wjg.v12.i13.2016. View

15.

Marcellin P, Kutala B . Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018; 38 Suppl 1:2-6. DOI: 10.1111/liv.13682. View

16.

Ramachandran P, Matchett K, Dobie R, Wilson-Kanamori J, Henderson N . Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis. Nat Rev Gastroenterol Hepatol. 2020; 17(8):457-472. DOI: 10.1038/s41575-020-0304-x. View

17.

Xu M, Xu H, Lin Y, Sun X, Wang L, Fang Z . LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis. Cell. 2019; 178(6):1478-1492.e20. DOI: 10.1016/j.cell.2019.07.021. View

18.

Mederacke I, Hsu C, Troeger J, Huebener P, Mu X, Dapito D . Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013; 4:2823. PMC: 4059406. DOI: 10.1038/ncomms3823. View

19.

Colella P, Ronzitti G, Mingozzi F . Emerging Issues in AAV-Mediated Gene Therapy. Mol Ther Methods Clin Dev. 2018; 8:87-104. PMC: 5758940. DOI: 10.1016/j.omtm.2017.11.007. View

20.

Tsay H, Yuan Q, Balakrishnan A, Kaiser M, Mobus S, Kozdrowska E . Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. J Hepatol. 2018; 70(4):722-734. DOI: 10.1016/j.jhep.2018.12.016. View